Analysis shows azeliragon 5mg/day resulted in steadily increasing delay in time to cognitive deterioration in mild Alzheimer’s disease patients Azeliragon designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation TORONTO --(BUSINESS WIRE)--Jul.
Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation – three of the principal causes of neuronal damage in AD HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 14, 2016-- vTv Therapeutics Inc.
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will
Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS --(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for
HIGH POINT, N.C. --(BUSINESS WIRE)--May 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and reported
Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 4, 2016-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
- Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer’s disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase Activator in Type 2 diabetes, with expected data readout in mid-2016 - Initiated LOGRA Phase 2b study with oral GLP-1R agonist in Type 2